Question 1

What are the potential benefits and risks of participating in this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL clinical trial (NCT06792825). Contact the study team or your healthcare provider for specific answers.

Question 2

How does this treatment compare to other options available for my condition?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL clinical trial (NCT06792825). Contact the study team or your healthcare provider for specific answers.

Question 3

What side effects should I expect from the treatments in this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL clinical trial (NCT06792825). Contact the study team or your healthcare provider for specific answers.

Question 4

How often will I need to come in for treatments and check-ups?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL clinical trial (NCT06792825). Contact the study team or your healthcare provider for specific answers.

Question 5

What should I do if I experience side effects during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL clinical trial (NCT06792825). Contact the study team or your healthcare provider for specific answers.

Question 6

Are there any specific eligibility requirements I should be aware of?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL clinical trial (NCT06792825). Contact the study team or your healthcare provider for specific answers.

What this study is about